Trial Profile
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Telithromycin 800 mg (Once Daily for 10 Days) as a Supplement to the Standard of Care for Patients With Acute Exacerbations of Asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Telithromycin (Primary)
- Indications Acute asthma; Bacterial infections
- Focus Therapeutic Use
- Acronyms TELICAST
- Sponsors Sanofi
- 15 Sep 2006 New trial record.